Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response


ARSLAN Ç., AKSOY S., DİZDAR Ö., KURT M., Guler N., Ozisik Y., ...More

TUMORI, vol.97, no.6, pp.711-716, 2011 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 97 Issue: 6
  • Publication Date: 2011
  • Doi Number: 10.1700/1018.11086
  • Journal Name: TUMORI
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.711-716

Abstract

Aims and background. Capecitabine, as all fluoropyrimidines, interferes with vitamin metabolism and may thus have an impact on hematopoiesis. It is metabolized to its active form 5-fluoruracil by the enzyme thymidine phosphorylase, which exists in higher concentrations in tumor tissue and liver than in normal tissues. In the study, we investigated the changes in mean corpuscular volume (MCV) of red blood cells and the possible correlation of these changes with the clinical outcome of capecitabine treatment in women with metastatic breast cancer.